ATAZANAVIR

/static/temp/default.svg Search structure
Trade Names
Synonyms
Status
Molecule Category Free-form
ATC J05AE08
UNII QZU4H47A3S
EPA CompTox DTXSID9048691

Structure

InChI Key AXRYRYVKAWYZBR-GASGPIRDSA-N
Smiles COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C
InChI
InChI=1S/C38H52N6O7/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47)/t29-,30-,31+,32+/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C38H52N6O7
Molecular Weight 704.87
AlogP 4.21
Hydrogen Bond Acceptor 9.0
Hydrogen Bond Donor 5.0
Number of Rotational Bond 14.0
Polar Surface Area 171.22
Molecular species NEUTRAL
Aromatic Rings 3.0
Heavy Atoms 51.0
Assay Description Organism Bioactivity Reference
Inhibitory activity against indinavir-resistant resistant strain of HIV-1. Human immunodeficiency virus 1 100.0 nM
Inhibitory activity against saquinavir-resistant resistant strain of HIV-1. Human immunodeficiency virus 1 100.0 nM
The percent reduction of the reverse transcriptase (RT) activity in HIV-1/MN-infected MT-2 cells. None 26.0 nM
Binding affinity for human immunodeficiency virus type 1 protease Human immunodeficiency virus 1 0.4 nM
Inhibition constant for human immunodeficiency virus type 1 protease Human immunodeficiency virus 1 0.24 nM
Inhibitory concentration against wild type Human immuno deficiency virus (EP13) was determined in an MT-4 cell line Human immunodeficiency virus 1 93.0 nM
Inhibitory concentration against wild type Human immuno deficiency virus (HXB2) was determined in an MT-4 cell line Human immunodeficiency virus 1 25.0 nM
Inhibitory concentration against wild type Human immuno deficiency virus (D545701) was determined in an MT-4 cell line Human immunodeficiency virus 1 70.0 nM
Antiviral activity against HIV1 HXB2 in MT4 cells None 25.0 nM
Antiviral activity against HIV1 EP13 in MT4 cells None 93.0 nM
Antiviral activity against HIV D545701 in MT4 cells None 70.0 nM
Inhibition of HIV1 Protease M1 variant by FRET based assay Human immunodeficiency virus 1 0.33 nM
Inhibition of HIV1 Protease M2 variant by FRET based assay Human immunodeficiency virus 1 0.009 nM
Inhibition of HIV1 Protease M3 variant by FRET based assay Human immunodeficiency virus 1 0.49 nM
Inhibition of HIV1 protease expressed in Escherichia coli Human immunodeficiency virus 1 2.7 nM
Antiviral activity against HIV1 in MT4 cells by XTT assay Human immunodeficiency virus 1 3.9 nM
Inhibition of HIV1 protease Human immunodeficiency virus 1 0.05 nM
Antiviral activity against HIV1 3B Human immunodeficiency virus 1 4.0 nM
Antiviral activity against HIV1 3B in presence of 50% human serum Human immunodeficiency virus 1 9.0 nM
Antiviral activity against wild type HIV1 Human immunodeficiency virus 1 15.0 nM
Antiviral activity against HIV1 mutant strain 1 Human immunodeficiency virus 1 92.0 nM
Antiviral activity against HIV1 mutant strain 2 Human immunodeficiency virus 1 48.0 nM
Antiviral activity against HIV1 mutant strain 3 Human immunodeficiency virus 1 23.0 nM
Antiviral activity against HIV1 mutant strain 4 Human immunodeficiency virus 1 95.0 nM
Antiviral activity against HIV1 mutant strain 5 Human immunodeficiency virus 1 266.0 nM
Antiviral activity against HIV1 mutant strain 6 Human immunodeficiency virus 1 134.0 nM
Antiviral activity against HIV1 mutant strain 7 Human immunodeficiency virus 1 74.0 nM
Antiviral activity against HIV1 LAI in MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 4.8 nM
Antiviral activity against HIV2 EHO in MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 2 5.0 nM
Antiviral activity against HIV2 ROD in MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 2 13.0 nM
Antiviral activity against HIV1 NL4-3 in MT4 cells by MTT assay Human immunodeficiency virus 1 4.2 nM
Antiviral activity against saquinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 326.0 nM
Antiviral activity against ritonavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 18.0 nM
Antiviral activity against idinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 60.0 nM
Antiviral activity against nelfinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 21.0 nM
Antiviral activity against atazanavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 3.0 nM
Antiviral activity against lopinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 40.0 nM
Antiviral activity against amprenavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 330.0 nM
Antiviral activity against HIV1 GRL98065p20 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 6.0 nM
Antiviral activity against HIV1 GRL98065p30 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 8.0 nM
Antiviral activity against HIV1 GRL98065p40 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 11.0 nM
Antiviral activity against wild type HIV1 ERS104prc X4 in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 3.8 nM
Antiviral activity against HIV1 MDR/TM X4 in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 38.0 nM
Antiviral activity against HIV1 MDR/MM R5 in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 45.0 nM
Antiviral activity against HIV1 MDR/JSL R5 in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 540.0 nM
Antiviral activity against HIV1 MDR/B X4 in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 250.0 nM
Antiviral activity against HIV1 MDR/C X4 in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 21.0 nM
Antiviral activity against HIV1 MDR/G X4 in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 32.0 nM
Antiviral activity against HIV1 92UG029 X4 subtype A in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 6.0 nM
Antiviral activity against HIV1 92UG037 subtype A R5 in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 2.5 nM
Antiviral activity against HIV1 BaL R5 subtype B in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 1.3 nM
Antiviral activity against HIV1 97ZA003 R5 subtype C in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 3.4 nM
Antiviral activity against HIV1 92TH019 R5 subtype E in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay Human immunodeficiency virus 1 2.7 nM
Inhibition of wild-type HIV1 BH10 protease expressed in Escherichia coli by spectrophotometric assay Human immunodeficiency virus 1 0.024 nM
Inhibition of HIV1 recombinant protease D30N/N88D mutant expressed in Escherichia coli by spectrophotometric assay Human immunodeficiency virus 1 0.055 nM
Inhibition of HIV1 recombinant protease M46I/A71V/V82T/I84V mutant expressed in Escherichia coli by spectrophotometric assay Human immunodeficiency virus 1 0.76 nM
Inhibition of HIV1 recombinant protease A71V/V82T/I84V mutant expressed in Escherichia coli by spectrophotometric assay Human immunodeficiency virus 1 0.23 nM
Inhibition of HIV1 recombinant protease V32I/I47A mutant expressed in Escherichia coli by spectrophotometric assay Human immunodeficiency virus 1 0.17 nM
Inhibition of HIV1 recombinant protease L10I/I15V/E35D/N37S/R41K/I62V/L63P/A71V/G73S/L90M mutant expressed in Escherichia coli by spectrophotometric assay Human immunodeficiency virus 1 0.076 nM
Inhibition of HIV1 recombinant protease L10I/L24I/L33F/M46L/154V/L63P/A71V/V82A/I84V mutant expressed in Escherichia coli by spectrophotometric assay Human immunodeficiency virus 1 1.2 nM
Inhibition of HIV1 recombinant protease L10F/L19I/K20R/L33F/E35D/M36I/R41K/F53L/I54V/L63P/H69K/A71V/T74P/I84V/L89M/L90M/I93L mutant expressed in Escherichia coli by spectrophotometric assay Human immunodeficiency virus 1 0.054 nM
Ratio of Ki for HIV1 recombinant protease D30N/N88D mutant to Ki for wild-type HIV1 BH10 protease Human immunodeficiency virus 1 2.3 nM
Ratio of Ki for HIV1 recombinant protease M46I/A71V/V82T/I84V mutant to Ki for wild-type HIV1 BH10 protease Human immunodeficiency virus 1 32.0 nM
Ratio of Ki for HIV1 recombinant protease A71V/V82T/I84V mutant to Ki for wild-type HIV1 BH10 protease Human immunodeficiency virus 1 9.4 nM
Ratio of Ki for HIV1 recombinant protease V32I/I47A mutant to Ki for wild-type HIV1 BH10 protease Human immunodeficiency virus 1 7.1 nM
Ratio of Ki for HIV1 recombinant protease L10I/I15V/E35D/N37S/R41K/I62V/L63P/A71V/G73S/L90M mutant to Ki for wild-type HIV1 BH10 protease Human immunodeficiency virus 1 3.2 nM
Ratio of Ki for HIV1 recombinant protease L10I/L24I/L33F/M46L/154V/L63P/A71V/V82A/I84V mutant to Ki for wild-type HIV1 BH10 protease expressed in Escherichia coli Human immunodeficiency virus 1 50.0 nM
Ratio of Ki for HIV1 recombinant protease L10F/L19I/K20R/L33F/E35D/M36I/R41K/F53L/I54V/L63P/H69K/A71V/T74P/I84V/L89M/L90M/I93L mutant to Ki for wild-type HIV1 BH10 protease Human immunodeficiency virus 1 2.3 nM
Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Human immunodeficiency virus 1 5.0 nM
Antiviral activity against HIV2 MS infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Human immunodeficiency virus 2 20.0 nM
Antiviral activity against HIV2 CBL-23 infected in human PBMC assessed as inhibition of virus production after 5 days by Lenti-RT activity assay Human immunodeficiency virus 2 39.0 nM
Antiviral activity against HIV2 CDC310319 isolate infected in human PBMC assessed as inhibition of virus production after 5 days by Lenti-RT activity assay Human immunodeficiency virus 2 110.0 nM
Antiviral activity against wild type HIV2 ROD infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay Human immunodeficiency virus 2 34.0 nM
Antiviral activity against HIV2 ROD with protease G17N mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay Human immunodeficiency virus 2 20.0 nM
Antiviral activity against HIV2 ROD with protease V47A mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay Human immunodeficiency virus 2 5.0 nM
Antiviral activity against HIV2 ROD with protease G17N/V47A mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay Human immunodeficiency virus 2 3.0 nM
Inhibition of HIV1 protease Human immunodeficiency virus 1 0.039 nM
Antiviral activity against wild type HIV1 NL4-3 infected in MT4 cells after 6 days by MTT assay Human immunodeficiency virus 1 4.0 nM
Antiviral activity against wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay Human immunodeficiency virus 1 1.5 nM
Antiviral activity against HIV1 BaL in human PBMC assessed as blockade of reverse transcriptase activity Human immunodeficiency virus 1 4.4 nM
Antiviral activity against HIV1 drug resistant mutant isolates from protease inhibitor treated HIV patient Human immunodeficiency virus 1 47.0 nM
Antiviral activity against HIV1 NL4-3 Human immunodeficiency virus 1 15.3 nM
Antiviral activity against wild-type HIV1 pNL4-3 infected in human MT4 cells after 5 days by MTT assay Human immunodeficiency virus 1 3.0 nM
Antiviral activity against HIV1 bearing protease gene with A17 mutation infected in human MT4 cells after 5 days by MTT assay Human immunodeficiency virus 1 250.0 nM
Antiviral activity against HIV1 bearing protease gene with B26 mutation infected in human MT4 cells after 5 days by MTT assay Human immunodeficiency virus 1 74.0 nM
Antiviral activity against HIV1 bearing protease gene with P25 mutation infected in human MT4 cells after 5 days by MTT assay Human immunodeficiency virus 1 298.0 nM
Inhibition of HIV1 protease expressed in Escherichia coli by fluorometric assay Human immunodeficiency virus 1 0.5 nM
Antiviral activity against HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 6 days by XTT assay Human immunodeficiency virus 1 8.0 nM
Antiviral activity against multi drug-resistant HIV1 isolate of subtype C in PHA-stimulated human PBMC assessed as inhibition of p24 antigen production Human immunodeficiency virus 1 45.0 nM
Antiviral activity against multi drug-resistant HIV1 isolate of subtype G in PHA-stimulated human PBMC assessed as inhibition of p24 antigen production Human immunodeficiency virus 1 29.0 nM
Antiviral activity against multi drug-resistant HIV1 isolate of subtype TM in PHA-stimulated human PBMC assessed as inhibition of p24 antigen production Human immunodeficiency virus 1 47.0 nM
Antiviral activity against multi drug-resistant HIV1 isolate of subtype MM in PHA-stimulated human PBMC assessed as inhibition of p24 antigen production Human immunodeficiency virus 1 40.0 nM
Antiviral activity against multi drug-resistant HIV1 isolate of subtype JSL in PHA-stimulated human PBMC assessed as inhibition of p24 antigen production Human immunodeficiency virus 1 635.0 nM
Antiviral activity against wild type HIV1 isolate ERS104pre in PHA-stimulated human PBMC assessed as inhibition of p24 antigen production Human immunodeficiency virus 1 3.0 nM
Antiviral activity against wild-type HIV1 pNL4-3 infected in human MT4 cells assessed as reduction in viral cytopathogenicity treated 1 hr post infection measured 5 days post infection in absence of human serum by MTT assay Human immunodeficiency virus 1 4.0 nM
Antiviral activity against wild-type HIV1 pNL4-3 infected in human MT4 cells assessed as reduction in viral cytopathogenicity treated 1 hr post infection measured 5 days post infection in presence of 50% human serum by MTT assay Human immunodeficiency virus 1 11.0 nM
Antiviral activity against wild-type HIV1 RF infected in human MT4 cells assessed as reduction in viral cytopathogenicity treated 1 hr post infection measured 5 days post infection in absence of human serum by MTT assay Human immunodeficiency virus 1 7.0 nM
Antiviral activity against wild-type HIV1 pNL4-3 infected in human MT4 cells assessed as reduction in viral cytopathogenicity after 5 days post dose by MTT assay Human immunodeficiency virus 1 67.0 nM
Antiviral activity against HIV1 A17 infected in human MT4 cells harboring protease L10F, V32I, M46I, I47V, Q58E, and I84V mutation derived from viral passages with Lopinavir assessed as reduction in viral cytopathogenicity treated 1 hr post infection measured 5 days post infection by MTT assay Human immunodeficiency virus 1 296.0 nM
Antiviral activity against HIV1 B26 infected in human MT4 cells harboring protease L33F, K45I, M46I, I50V, I54V, A71V, and V82F mutation derived from viral passages with Lopinavir assessed as reduction in viral cytopathogenicity treated 1 hr post infection measured 5 days post infection by MTT assay Human immunodeficiency virus 1 51.0 nM
Antiviral activity against HIV1 P25 infected in human MT4 cells harboring protease L10F, G16E, V32I, M46I, I47A, H69Y, I84V, and T91S mutation derived from viral passages with Lopinavir assessed as reduction in viral cytopathogenicity treated 1 hr post infection measured 5 days post infection by MTT assay Human immunodeficiency virus 1 355.0 nM
Antiviral activity against HIV 2 subtype A clinical isolate expressing 14H-17D-43T-68N/D protease gene sequence from HIV2 infected patient plasma and PBMC obtained before compound treatment measured after 13 months Human immunodeficiency virus 2 70.0 nM
Antiviral activity against HIV 2 subtype A clinical isolate expressing 5L/F-14Y/H-17G/D-43T-54I/M-62V/A-70R/K-71I protease gene sequence from HIV2 infected patient plasma and PBMC obtained at T1 during compound treatment measured after 13 months Human immunodeficiency virus 2 300.0 nM
Antiviral activity against HIV 2 subtype A clinical isolate expressing 14H-60K/N-65E protease gene sequence from HIV2 infected patient plasma and PBMC obtained before compound treatment measured after 13 months Human immunodeficiency virus 2 40.0 nM
Antiviral activity against HIV 2 subtype A clinical isolate expressing 54M-65E-71I-74N-90M protease gene sequence from HIV2 infected patient plasma and PBMC obtained at T1 during compound treatment measured after 13 months Human immunodeficiency virus 2 400.0 nM
Antiviral activity against HIV 2 subtype A clinical isolate expressing 10I-17D-40D-43I-46V-66V/A-70R/K protease gene sequence from HIV2 infected patient plasma and PBMC obtained before compound treatment measured after 13 months Human immunodeficiency virus 2 100.0 nM
Antiviral activity against HIV 2 subtype A clinical isolate expressing 10I-17D-40D-43I-45K/R-46V-54M-64I/V-69K/R-71V/I-90M protease gene sequence from HIV2 infected patient plasma and PBMC obtained at T1 during compound treatment measured after 13 months Human immunodeficiency virus 2 200.0 nM
Antiviral activity against HIV 2 subtype A clinical isolate expressing 14H-40D-70K-72R/K-91T/S protease gene sequence from HIV2 infected patient plasma and PBMC obtained before compound treatment measured after 13 months Human immunodeficiency virus 2 40.0 nM
Antiviral activity against HIV 2 subtype A clinical isolate expressing 10I-40D-43I-70K-82F-84V-85L-89V-90M-91T/L-98N/K protease gene sequence from HIV2 infected patient plasma and PBMC obtained at T1 during compound treatment measured after 13 months Human immunodeficiency virus 2 40.0 nM
Antiviral activity against HIV 2 subtype A clinical isolate expressing 10V/I-40D-43I-56V-70K-82F-84V-89V-90M protease gene sequence from HIV2 infected patient plasma and PBMC obtained at T2 during compound treatment measured after 3 months Human immunodeficiency virus 2 400.0 nM
Antiviral activity against HIV 2 subtype B clinical isolate expressing 14Y-61N-99L protease gene sequence from HIV2 infected patient plasma and PBMC obtained before compound treatment measured after 13 months Human immunodeficiency virus 2 60.0 nM
Antiviral activity against HIV 2 subtype B clinical isolate expressing 14Y-19P-61N-64V-71I-90M-95I protease gene sequence from HIV2 infected patient plasma and PBMC obtained at T2 during compound treatment measured after 3 months Human immunodeficiency virus 2 200.0 nM
Antiviral activity against HIV 2 subtype B clinical isolate expressing 12T-14Y-19P-40N-41D-61N-62I-96S-99L protease gene sequence from HIV2 infected patient plasma and PBMC obtained before compound treatment measured after 13 months Human immunodeficiency virus 2 200.0 nM
Antiviral activity against HIV 2 subtype B clinical isolate expressing 12Q-14R-17G/D-19P-61N-62I-92A protease gene sequence from HIV2 infected patient plasma and PBMC obtained before compound treatment measured after 13 months Human immunodeficiency virus 2 30.0 nM
Antiviral activity against HIV 2 subtype B clinical isolate expressing 41D protease gene sequence from HIV2 infected patient plasma and PBMC obtained before compound treatment measured after 13 months Human immunodeficiency virus 2 30.0 nM
Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) after 13 months Human immunodeficiency virus type 2 (ISOLATE ROD) 30.0 nM
Antiviral activity against Human immunodeficiency virus type 1 (BRU ISOLATE) after 13 months Human immunodeficiency virus type 1 (BRU ISOLATE) 7.0 nM
Antiviral activity against HIV 2 subtype H expressing 10I-40P-41Y-60H-63N-70T-73G-89L-92E protease gene sequence from HIV2 infected patient plasma and PBMC obtained before compound treatment measured after 13 months Human immunodeficiency virus 2 100.0 nM
Antiviral activity against HIV1 subtype B harboring protease polymorphism at M36 position M46I, I50L, N88S mutant gene infected in human cord blood mononuclear cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Human immunodeficiency virus 1 183.0 nM
Antiviral activity against HIV1 subtype C harboring protease L23I, M46I/M, L89T mutant gene and polymorphism at M36 position infected in human cord blood mononuclear cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Human immunodeficiency virus 1 88.0 nM
Antiviral activity against HIV1 subtype C harboring protease E35G mutant gene and polymorphism at I36 position infected in human cord blood mononuclear cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Human immunodeficiency virus 1 3.7 nM
Antiviral activity against HIV1 subtype CRF02_AG harboring protease polymorphism at M36 position and I50FILV, A71V mutant gene infected in human cord blood mononuclear cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Human immunodeficiency virus 1 9.3 nM
Antiviral activity against HIV1 subtype B harboring protease polymorphism at I36 position and M46I, I50L, N88S mutant gene infected in human cord blood mononuclear cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Human immunodeficiency virus 1 7.1 nM
Antiviral activity against HIV1 subtype CRF02_AG harboring protease polymorphism at I36 position and I50FILV, A71V mutant gene infected in human cord blood mononuclear cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Human immunodeficiency virus 1 18.6 nM
Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of p24 gag protein production by ELISA Human immunodeficiency virus 1 4.3 nM
Antiviral activity against HIV1 NL4-3 harboring L10I/G48V/I54V/L90M amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of saquinavir by ELISA Human immunodeficiency virus 1 320.0 nM
Antiviral activity against HIV1 NL4-3 harboring L10F/V32I/M46I/I54M//A71V/I84V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of amprenavir by ELISA Human immunodeficiency virus 1 3.2 nM
Antiviral activity against HIV1 NL4-3 harboring L10F/L24I/M46I/L63P/A71V/G73S/V82T amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of indinavir by ELISA Human immunodeficiency virus 1 63.0 nM
Antiviral activity against HIV1 NL4-3 harboring L10F/D30N/K45I/A71V/T74S amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of nelfinavir by ELISA Human immunodeficiency virus 1 24.0 nM
Antiviral activity against HIV1 NL4-3 harboring M46I/V82F/I84V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of ritonavir by ELISA Human immunodeficiency virus 1 21.0 nM
Antiviral activity against HIV1 NL4-3 harboring L10F/M46I/I54V/V82A amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 1 uM of Lopinavir by ELISA Human immunodeficiency virus 1 41.0 nM
Antiviral activity against HIV1 NL4-3 harboring L23I/K43I/M46I/I50L/G51A/A71V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 1 uM of atazanavir by ELISA Human immunodeficiency virus 1 310.0 nM
Antiviral activity against HIV1 NL4-3 harboring L10F/L33F/M46I/I47V/Q58E/V82I/I84V/I85V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of GRL-02031 by ELISA Human immunodeficiency virus 1 36.0 nM
Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells by MTT assay Human immunodeficiency virus 1 4.0 nM
Antiviral activity against HIV1 expressing protease L10I/G48V/I54V/A71V/I84V/L90M mutant infected in human MT4 cells selected at 5 uM of saquinavir by MTT assay Human immunodeficiency virus 1 210.0 nM
Antiviral activity against HIV1 expressing protease L10F/D30N/K45I/A71V/T74S mutant infected in human MT4 cells selected at 5 uM of nelfinavir by MTT assay Human immunodeficiency virus 1 27.0 nM
Antiviral activity against HIV1 expressing protease L10F/M46I/I50V/A71V/I84V/L90M mutant infected in human MT4 cells selected at 5 uM of amprenavir by MTT assay Human immunodeficiency virus 1 6.0 nM
Antiviral activity against HIV1 expressing protease L10F/M46I/I54V/V82A mutant infected in human MT4 cells selected at 5 uM of Lopinavir by MTT assay Human immunodeficiency virus 1 36.0 nM
Antiviral activity against wild type HIV1 ERS104 containing protease L36P mutant infected in human PHA-PBMC cells by MTT assay Human immunodeficiency virus 1 2.0 nM
Antiviral activity against multidrug-resistant HIV1 isolate B containing protease L10I, K14R, L33I, M36I,M46I, F53I, K55R, I62V, L63P, A71V, G73S, V82A, L90M, and I93L mutant infected in human PHA-PBMC cells by MTT assay Human immunodeficiency virus 1 200.0 nM
Antiviral activity against multidrug-resistant HIV1 isolate C containing protease L10I, I15V, K20R, L24I, M36I, M46L, I54V, I62V, L63P, K70Q, V82A, and L89M mutant infected in human PHA-PBMC cells by MTT assay Human immunodeficiency virus 1 65.0 nM
Antiviral activity against multidrug-resistant HIV1 isolate G containing L10I, V11I, T12E, I15V, L19I,R41K, M46L, L63P, A71T, V82A, and L90M mutant infected in human PHA-PBMC cells by MTT assay Human immunodeficiency virus 1 33.0 nM
Antiviral activity against multidrug-resistant HIV1 isolate TM containing L10I, K14R, R41K, M46L, I54V, L63P, A71V, V82A, L90M, and I93L mutant infected in human PHA-PBMC cells by MTT assay Human immunodeficiency virus 1 65.0 nM
Antiviral activity against multidrug-resistant HIV1 isolate MM containing L10I, K43T, M46L, I54V, L63P, A71V, V82A, L90M, and Q92K mutant infected in human PHA-PBMC cells by MTT assay Human immunodeficiency virus 1 180.0 nM
Antiviral activity against multidrug-resistant HIV1 isolate JSL containing L10I, L24I, I33F, E35D, M36I, N37S, M46L, I54V, R57K, I62V, L63P, A71V, G73S, and V82A mutant infected in human PHA-PBMC cells by MTT assay Human immunodeficiency virus 1 430.0 nM
Antiviral activity against HIV1 expressing protease L10I/L24I/M46I/V82I/I84V mutant infected in human MT4 cells selected after 50 passages of GRL-216 by MTT assay Human immunodeficiency virus 1 14.0 nM
Antiviral activity against HIV1 expressing protease L10F/M46I/T91S mutant infected in human MT4 cells selected at 1 uM of GRL-246 by MTT assay Human immunodeficiency virus 1 32.0 nM
Antiviral activity against HIV1 expressing protease L10F/M46L/I50V/A71Vmutant infected in human MT4 cells selected at 1 uM of GRL-286 by MTT assay Human immunodeficiency virus 1 21.0 nM
Antiviral activity against HIV1 expressing protease L10F/M46M,I/Q61Q mutant infected in human MT4 cells selected at 1 uM of GRL-396 by MTT assay Human immunodeficiency virus 1 24.0 nM
Antiviral activity against wild type HIV-1 ERS104 pre infected in human PHA-PBM cells assessed as inhibition of p24 Gag protein production Human immunodeficiency virus 1 2.7 nM
Antiviral activity against HIV-1 MDR/B infected in human PHA-PBM cells assessed as inhibition of p24 Gag protein production Human immunodeficiency virus 1 470.0 nM
Antiviral activity against HIV-1 MDR/C infected in human PHA-PBM cells assessed as inhibition of p24 Gag protein production Human immunodeficiency virus 1 39.0 nM
Antiviral activity against HIV-1 MDR/G infected in human PHA-PBM cells assessed as inhibition of p24 Gag protein production Human immunodeficiency virus 1 19.0 nM
Antiviral activity against HIV-1 MDR/TM infected in human PHA-PBM cells assessed as inhibition of p24 Gag protein production Human immunodeficiency virus 1 75.0 nM
Antiviral activity against HIV-1 MDR/MM infected in human PHA-PBM cells assessed as inhibition of p24 Gag protein production Human immunodeficiency virus 1 205.0 nM
Antiviral activity against HIV-1 MDR/JSL infected in human PHA-PBM cells assessed as inhibition of p24 Gag protein production Human immunodeficiency virus 1 293.0 nM
Inhibition of HIV1 subtype C protease expressed in Escherichia coli BL21 assessed as hydrolysis of substrate using chromogenic substrate Lys-Ala-Arg-Val-Nle-p-nitro-Phe-Glu-Ala-Nle-NH2 by spectrophotometric analysis Human immunodeficiency virus 1 4.0 nM
Inhibition of HIV1 subtype C protease Q7K mutant expressed in Escherichia coli BL21 (DE3) pLysS using Lys-Ala-Arg-Val-Nle-p-nitro-Phe-Glu-Ala-Nle-NH2 as substrate by spectrophotometry Human immunodeficiency virus 1 4.0 nM
Antiviral activity against multidrug-resistant HIV1 106-PR infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay Human immunodeficiency virus 1 324.0 nM
Inhibition of HIV1 protease expressed in Escherichia coli using DABCYL-Abu-Ser-Gln-ASN-Tyr-Pro-Ile-Val-Gln-EDANS as substrate preincubated for 20 mins measured for 45 mins by fluorometry Human immunodeficiency virus 1 2.7 nM
Inhibition of South African HIV1 subtype C protease expressed in Escherichia coli BL21S4 (DE3)pLysS cells using Lys-Ala-Arg-Val-Nle-p-nitro-Phe-Glu-Ala-Nle-NH2 as substrate by spectrophotometry Human immunodeficiency virus 1 4.0 nM
Antiviral activity against Human immunodeficiency virus 1 3B expressing wild-type protease infected in human MT4 cells Human immunodeficiency virus 1 6.9 nM
Antiviral activity against Human immunodeficiency virus 1 isolate M1 expressing protease L10I, M46I, I64V, I84V, L90M, I93L mutant infected in human MT4 cells Human immunodeficiency virus 1 58.0 nM
Antiviral activity against Human immunodeficiency virus 1 isolate M2 expressing protease L10I, I13V, M46I, I50V, L63P, L76V mutant infected in human MT4 cells Human immunodeficiency virus 1 3.2 nM
Antiviral activity against Human immunodeficiency virus 1 isolate M3 expressing protease L10I, K20R, M36I, G48V, I62V, A71V, V82A, I93L mutant infected in human MT4 cells Human immunodeficiency virus 1 60.5 nM
Antiviral activity against Human immunodeficiency virus 1 3B expressing wild-type protease infected in human MT4 cells in presence of 50% human serum Human immunodeficiency virus 1 13.3 nM
Inhibition of wild type Human immunodeficiency virus protease expressed in Escherichia coli using ArgGlu(EDANS)SerGlnAsnTyrProIleValGlnLys(DABCYL)Arg as substrate preincubated with compound for 0.5 to 1 min measured by fluorometric analysis at pH 6.5 Human immunodeficiency virus 0.1 nM
Inhibition of Human immunodeficiency virus protease M8 mutant expressed in Escherichia coli using ArgGlu(EDANS)SerGlnAsnTyrProIleValGlnLys(DABCYL)Arg as substrate preincubated with compound for 0.5 to 1 min measured by fluorometric analysis at pH 6.5 Human immunodeficiency virus 2.8 nM
Inhibition of Human immunodeficiency virus protease M9 mutant expressed in Escherichia coli using ArgGlu(EDANS)SerGlnAsnTyrProIleValGlnLys(DABCYL)Arg as substrate preincubated with compound for 0.5 to 1 min measured by fluorometric analysis at pH 6.5 Human immunodeficiency virus 84.0 nM
Inhibition of Human immunodeficiency virus protease M10 mutant expressed in Escherichia coli using ArgGlu(EDANS)SerGlnAsnTyrProIleValGlnLys(DABCYL)Arg as substrate preincubated with compound for 0.5 to 1 min measured by fluorometric analysis at pH 6.5 Human immunodeficiency virus 171.0 nM
Antiviral activity against Human immunodeficiency virus 1 HXB2 expressing wild type protease infected in human MT4 cells after 5 days by MTT assay Human immunodeficiency virus 1 3.5 nM
Antiviral activity against Human immunodeficiency virus 1 HXB2 expressing protease M8 mutant infected in human MT4 cells after 5 days by MTT assay Human immunodeficiency virus 1 750.0 nM
Antiviral activity against Human immunodeficiency virus 1 HXB2 expressing protease M3 mutant infected in human MT4 cells after 5 days by MTT assay Human immunodeficiency virus 1 350.0 nM
Antiviral activity against Human immunodeficiency virus 1 HXB2 expressing protease M4 mutant infected in human MT4 cells after 5 days by MTT assay Human immunodeficiency virus 1 600.0 nM
Antiviral activity against Human immunodeficiency virus 1 HXB2 expressing protease M5 mutant infected in human MT4 cells after 5 days by MTT assay Human immunodeficiency virus 1 280.0 nM
Antiviral activity against Human immunodeficiency virus 1 HXB2 expressing protease M6 mutant infected in human MT4 cells after 5 days by MTT assay Human immunodeficiency virus 1 430.0 nM
Antiviral activity against Human immunodeficiency virus 1 HXB2 expressing protease M7 mutant infected in human MT4 cells after 5 days by MTT assay Human immunodeficiency virus 1 105.0 nM
Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting Homo sapiens 95.0 %
Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting Homo sapiens 92.6 %
Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting Homo sapiens 90.1 %
Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting Homo sapiens 370.0 nM Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting Homo sapiens 400.0 nM
Inhibition of wild type C-South African Human immunodeficiency virus 1 protease using chromogenic peptide H-1048 as substrate by UV spectrophotometric analysis Human immunodeficiency virus 1 4.0 nM
Inhibition of C-south african HIV-1 protease assessed as hydrolysis of the chromogenic peptide substrate Lys-Ala-Arg-Val-Nle-p-nitro-Phe-Glu-Ala-Nle-NH2 Human immunodeficiency virus 1 4.0 nM
Antiviral activity against Human immunodeficiency virus 1 3B clinical isolate harboring L10I/K20R/M36I/G48V/ I62V/A71V/V82A/I93L protease mutant infected in human MT4 cells assessed as inhibition of viral replication Human immunodeficiency virus 1 61.0 nM
Antiviral activity against Human immunodeficiency virus 1 3B clinical isolate harboring L10I/I13V/M46I/I50V/L63P/L76V protease mutant infected in human MT4 cells assessed as inhibition of viral replication Human immunodeficiency virus 1 3.2 nM
Antiviral activity against Human immunodeficiency virus 1 3B clinical isolate harboring L10I/M46I/I64V/I84V/L90M/I93L protease mutant infected in human MT4 cells assessed as inhibition of viral replication Human immunodeficiency virus 1 57.0 nM
Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of viral replication in presence of 50% human plasma Human immunodeficiency virus 1 13.0 nM
Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of viral replication Human immunodeficiency virus 1 6.8 nM
Inhibition of HIV1 protease using fluorogenic hexapeptide substrate (2-aminobenzoyl)Thr-Ile-Nle-(p-nitro)Phe-Gln-Arg by fluorimeter Human immunodeficiency virus 1 0.0479 nM
Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as virus-induced cytopathic effect after 5 days by XTT assay Human immunodeficiency virus 1 2.2 nM
Inhibition of HIV1 RF protease expressed in Escherichia coli BL21 (DE3) using DABCYL-delta-Abu-Ser-Gln-ASN-Tyr-Pro-Ile-Val-Gln-EDANS as substrate after 30 mins by fluorescence assay Human immunodeficiency virus 1 2.7 nM
Antiviral activity against HIV1 RF infected in human MT2 cells after 4 to 7 days by ELISA Human immunodeficiency virus 1 3.9 nM
Inhibition of wild-type HIV1 protease expressed in Escherichia coli assessed as reduction in product formation preincubated for 30 mins followed by addition of Val-Ser-Gln-Asn-(beta-naphtyl)Ala-Pro-Ile-Val as substrate measured after 1 hr Human immunodeficiency virus 1 0.04 nM
Antiviral activity against amprenavir-resistant HIV1 NL4-3 harboring protease L10F/V32I/L33F/M46L/I54M/A71V mutant infected in human MT4 cells assessed as reduction in p24 Gag protein production after 7 days by chemiluminescent enzyme immunoassay Human immunodeficiency virus 1 3.8 nM
Antiviral activity against lopinavir-resistant HIV1 NL4-3 harboring protease L10F/V32I/M46I/I47A/A71V/I84V mutant infected in human MT4 cells assessed as reduction in p24 Gag protein production after 7 days by chemiluminescent enzyme immunoassay Human immunodeficiency virus 1 45.0 nM
Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells assessed as reduction in p24 Gag protein production after 7 days by chemiluminescent enzyme immunoassay Human immunodeficiency virus 1 4.2 nM
Antiviral activity against nelfinavir-resistant HIV1 NL4-3 harboring protease L10F/K20T/D30N/K45I/A71V/V77I mutant infected in human MT4 cells assessed as reduction in p24 Gag protein production after 7 days by chemiluminescent enzyme immunoassay Human immunodeficiency virus 1 17.0 nM
Antiviral activity against saquinavir-resistant HIV1 NL4-3 harboring protease L10I/N37D/G48V/I54V/L63P/G73C/I84V/L90M mutant infected in human MT4 cells assessed as reduction in p24 Gag protein production after 7 days by chemiluminescent enzyme immunoassay Human immunodeficiency virus 1 510.0 nM
Antiviral activity against indinavir-resistant HIV1 NL4-3 harboring protease L10F/L24I/M46I/I54V/L63P/A71V/G73S/V82T mutant infected in human MT4 cells assessed as reduction in p24 Gag protein production after 7 days by chemiluminescent enzyme immunoassay Human immunodeficiency virus 1 62.0 nM
Inhibition of HIV1 protease expressed in Escherichia coli using Val-Ser-Gln-Asn-(beta-naphtyl)Ala-Pro-Ile-Val as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by mass spectrometric method Human immunodeficiency virus 1 0.04 nM
Antiviral activity against HIV1 infected in GFP expressing human MT4 cells assessed as inhibition of viral replication after 24 hrs in presence of 50% normal human serum Human immunodeficiency virus 1 12.0 nM
Inhibition of HIV1 NL4-3 protease assessed as decrease in viral replication in human MT2 cells after 4 days by luciferase reporter gene assay Human immunodeficiency virus 1 0.7 nM
Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells assessed as reduction in p24 Gag protein production after 7 days by chemiluminescent enzyme immunoassay Human immunodeficiency virus 1 3.3 nM
Antiviral activity against LPV resistant HIV1 harboring protease L10F/M46/I54V/V82A mutant infected in human MT4 cells assessed as reduction in p24 Gag protein production after 7 days by chemiluminescent enzyme immunoassay Human immunodeficiency virus 1 29.0 nM
Antiviral activity against APV resistant HIV1 harboring protease L10F/M46I/I50V/I85V mutant infected in human MT4 cells assessed as reduction in p24 Gag protein production after 7 days by chemiluminescent enzyme immunoassay Human immunodeficiency virus 1 70.0 nM
Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in p24 Gag protein production after 7 days by automated chemiluminescent enzyme immunoassay Human immunodeficiency virus 1 0.89 nM
Antiviral activity against lopinavir-resistant HIV1 infected in human MT4 cells assessed as reduction in p24 Gag protein production after 7 days by automated chemiluminescent enzyme immunoassay Human immunodeficiency virus 1 293.0 nM
Antiviral activity against amprenavir-resistant HIV1 infected in human MT4 cells assessed as reduction in p24 Gag protein production after 7 days by automated chemiluminescent enzyme immunoassay Human immunodeficiency virus 1 2.0 nM
Inhibition of recombinant human UGT1A1 using bilirubin as substrate preincubated for 5 mins followed by substrate addition and measured after 40 mins by LC-MS/MS analysis Homo sapiens 300.0 nM
Inhibition of recombinant cynomolgus monkey UGT1A1 using bilirubin as substrate preincubated for 5 mins followed by substrate addition and measured after 40 mins by LC-MS/MS analysis Macaca fascicularis 700.0 nM
Inhibition of UGT1A1 in human liver microsomes using beta-estradiol as substrate preincubated for 5 mins followed by substrate addition and measured after 40 mins by LC-MS/MS analysis Homo sapiens 600.0 nM
Inhibition of HIV1 protease activity Human immunodeficiency virus 1 0.3 nM
Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as reduction in viral yield measured after 4 days by EnduRen live cell substrate based luciferase reporter gene assay Human immunodeficiency virus 1 0.7 nM
Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in p24 Gag protein production Human immunodeficiency virus 1 4.0 nM
Antiviral activity against lopinavir resistant HIV1 harboring protease L10F/V32I/M46I/I47A/A71V/I84V mutant infected in human MT4 cells assessed as inhibition of p24 Gag production Human immunodeficiency virus 1 430.0 nM
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 25.33 % SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 2.3 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.07 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.03 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.03 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.07 %
Antiviral activity against HIV1 NL4-3 infected in human MT4 cells incubated for 7 days by fully automated chemiluminescent enzyme immunoassay Human immunodeficiency virus 1 5.0 nM
Antiviral activity against LPV-resistant HIV1 infected in human MT4 cells incubated for 7 days by fully automated chemiluminescent enzyme immunoassay Human immunodeficiency virus 1 309.0 nM

Environmental Exposure

Environmental Exposure Map
Countries
Croatia
Romania

Cross References

Resources Reference
ChEBI 37924
ChEMBL CHEMBL1163
DrugBank DB01072
DrugCentral 254
FDA SRS QZU4H47A3S
Human Metabolome Database HMDB0015205
Guide to Pharmacology 11138
PDB DR7
PharmGKB PA10251
PubChem 148192
SureChEMBL SCHEMBL41696
ZINC ZINC000003941496
CONTENTS